Out of 929 patients with invasive stage I-II breast cancer who underwent conservative breast surgery, 663 (71.4%) were treated, after surgery, with adjuvant systemic therapy (chemotherapy± anti-HER2 agent or endocrine therapy). The gene discussed is ERBB2; the disease is breast carcinoma.